Advances in COVID-19 Vaccines and Neutralizing Antibody
The rapid and unprecedented spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) has caused millions of deaths worldwide. Additioanlly, it has put pressure on healthcare systems everywhere. In order to control the spread of coro...
में बचाया:
| स्वरूप: | Online |
|---|---|
| भाषा: | अंग्रेज़ी |
| प्रकाशित: |
MDPI - Multidisciplinary Digital Publishing Institute
2025
|
| विषय: | |
| ऑनलाइन पहुंच: | ONIX_20250220_9783725820405_84 |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
| _version_ | 1869520179763871744 |
|---|---|
| collection | Directory of Open Access Books |
| description | The rapid and unprecedented spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) has caused millions of deaths worldwide. Additioanlly, it has put pressure on healthcare systems everywhere. In order to control the spread of coronavirus disease, as many as 31 COVID-19 vaccines have been approved for emergency use to date, and over 10 billion doses have been administered globally. However, many new variants of SARS-CoV-2 have emerged since vaccine development, with high transmissibility and an ability to escape immune responses. An antibody immune response is important for the clearance of the virus and critical for the generation of memory response to prevent reinfection. SARS-CoV-2 generates a virus-specific IgM, and IgG and neutralizing IgG response in the days following infection. However, the IgG response wanes over time and, in some cases, leads to only partial protection. There is a need for further research in this field to understand the measure/degree of long-term protection conferred by the vaccine, vaccine-driven pathology and immune differences among patients. This necessitates the critical evaluation of vaccine efficiency to expedite vaccine research. |
| format | Online |
| id | doab-20.500.12854ir-152720 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1527202025-02-20T12:57:56Z Advances in COVID-19 Vaccines and Neutralizing Antibody Jaiswal, Rishi Basu, Srijani Gupta, Suman Gupta, Sneh Lata neutralizing antibody SARS-CoV-2 pre-clinical trials clinical trials heterologous protection trained immunity adaptive immunity immunology pandemic COVID-19 humoral response anti-spike antibodies peritoneal dialysis chronic kidney disease booster n/a anti-SARS-CoV-2 IgM immunity secondary response vaccination COVID-19 vaccine iron deficiency humoral immunity ELISA MIS-C Omicron EUA serology vaccine durable immunity emerging variants protection immunogenicity inactivated vaccine S1 RBD safety seroconversion TURKOVAC SARS-CoV-2 vaccine neutralizing antibodies mutations vaccine genes cross protection receptor binding domain spike protein nucleocapsid protein multiple sclerosis disease-modifying therapies antibodies vaccines Palestine mRNA vaccine adenovirus vaccine thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBP Health systems and services::MBPK Mental health services The rapid and unprecedented spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) has caused millions of deaths worldwide. Additioanlly, it has put pressure on healthcare systems everywhere. In order to control the spread of coronavirus disease, as many as 31 COVID-19 vaccines have been approved for emergency use to date, and over 10 billion doses have been administered globally. However, many new variants of SARS-CoV-2 have emerged since vaccine development, with high transmissibility and an ability to escape immune responses. An antibody immune response is important for the clearance of the virus and critical for the generation of memory response to prevent reinfection. SARS-CoV-2 generates a virus-specific IgM, and IgG and neutralizing IgG response in the days following infection. However, the IgG response wanes over time and, in some cases, leads to only partial protection. There is a need for further research in this field to understand the measure/degree of long-term protection conferred by the vaccine, vaccine-driven pathology and immune differences among patients. This necessitates the critical evaluation of vaccine efficiency to expedite vaccine research. 2025-02-20T12:57:53Z 2025-02-20T12:57:53Z 2024 book ONIX_20250220_9783725820405_84 9783725820405 9783725820399 https://directory.doabooks.org/handle/20.500.12854/152720 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/9928 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-2039-9 10.3390/books978-3-7258-2039-9 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725820405 9783725820399 174 Basel open access |
| spellingShingle | neutralizing antibody SARS-CoV-2 pre-clinical trials clinical trials heterologous protection trained immunity adaptive immunity immunology pandemic COVID-19 humoral response anti-spike antibodies peritoneal dialysis chronic kidney disease booster n/a anti-SARS-CoV-2 IgM immunity secondary response vaccination COVID-19 vaccine iron deficiency humoral immunity ELISA MIS-C Omicron EUA serology vaccine durable immunity emerging variants protection immunogenicity inactivated vaccine S1 RBD safety seroconversion TURKOVAC SARS-CoV-2 vaccine neutralizing antibodies mutations vaccine genes cross protection receptor binding domain spike protein nucleocapsid protein multiple sclerosis disease-modifying therapies antibodies vaccines Palestine mRNA vaccine adenovirus vaccine thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBP Health systems and services::MBPK Mental health services Advances in COVID-19 Vaccines and Neutralizing Antibody |
| title | Advances in COVID-19 Vaccines and Neutralizing Antibody |
| title_full | Advances in COVID-19 Vaccines and Neutralizing Antibody |
| title_fullStr | Advances in COVID-19 Vaccines and Neutralizing Antibody |
| title_full_unstemmed | Advances in COVID-19 Vaccines and Neutralizing Antibody |
| title_short | Advances in COVID-19 Vaccines and Neutralizing Antibody |
| title_sort | advances in covid 19 vaccines and neutralizing antibody |
| topic | neutralizing antibody SARS-CoV-2 pre-clinical trials clinical trials heterologous protection trained immunity adaptive immunity immunology pandemic COVID-19 humoral response anti-spike antibodies peritoneal dialysis chronic kidney disease booster n/a anti-SARS-CoV-2 IgM immunity secondary response vaccination COVID-19 vaccine iron deficiency humoral immunity ELISA MIS-C Omicron EUA serology vaccine durable immunity emerging variants protection immunogenicity inactivated vaccine S1 RBD safety seroconversion TURKOVAC SARS-CoV-2 vaccine neutralizing antibodies mutations vaccine genes cross protection receptor binding domain spike protein nucleocapsid protein multiple sclerosis disease-modifying therapies antibodies vaccines Palestine mRNA vaccine adenovirus vaccine thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBP Health systems and services::MBPK Mental health services |
| topic_facet | neutralizing antibody SARS-CoV-2 pre-clinical trials clinical trials heterologous protection trained immunity adaptive immunity immunology pandemic COVID-19 humoral response anti-spike antibodies peritoneal dialysis chronic kidney disease booster n/a anti-SARS-CoV-2 IgM immunity secondary response vaccination COVID-19 vaccine iron deficiency humoral immunity ELISA MIS-C Omicron EUA serology vaccine durable immunity emerging variants protection immunogenicity inactivated vaccine S1 RBD safety seroconversion TURKOVAC SARS-CoV-2 vaccine neutralizing antibodies mutations vaccine genes cross protection receptor binding domain spike protein nucleocapsid protein multiple sclerosis disease-modifying therapies antibodies vaccines Palestine mRNA vaccine adenovirus vaccine thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBP Health systems and services::MBPK Mental health services |
| url | ONIX_20250220_9783725820405_84 |